Distinguished in New Daily Persistent Headache (NDPH)

Dr. Deborah I. Friedman

Neurology | Ophthalmology
12740 Hillcrest Rd Ste 269, 
Dallas, TX 
Distinguished in New Daily Persistent Headache (NDPH)
12740 Hillcrest Rd Ste 269, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Deborah Friedman is a Neurologist and an Ophthalmologist in Dallas, Texas. Dr. Friedman is rated as a Distinguished provider by MediFind in the treatment of New Daily Persistent Headache (NDPH). Her top areas of expertise are Pseudotumor Cerebri Syndrome, Migraine, Headache, and Increased Intracranial Pressure.

Her clinical research consists of co-authoring 148 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Ophthalmology
Licenses
Ophthalmology in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

12740 Hillcrest Rd Ste 269, Dallas, TX 75230

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Preventing Depression and Anxiety: a Pilot Study of a Cystic-fibrosis Specific Cognitive-behavioral Therapy Intervention for Adolescents With CF
Preventing Depression and Anxiety: a Pilot Study of a Cystic-fibrosis Specific Cognitive-behavioral Therapy Intervention for Adolescents With CF
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches
Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Drug
Study Drug: C213 Microneedle System
Study Phase: Phase 2/Phase 3
A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines. (Premium II)
A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines. (Premium II)
Enrollment Status: Completed
Publish Date: September 11, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: August 19, 2020
Intervention Type: Drug
Study Phase: Phase 3
Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache
Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache
Enrollment Status: Unknown
Publish Date: June 26, 2018
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials

148 Total Publications

Telemedicine is effective and safe for clinical management of patients with headache disorders: An American Headache Society position statement.
Telemedicine is effective and safe for clinical management of patients with headache disorders: An American Headache Society position statement.
Journal: Headache
Published: August 14, 2025
Similar Doctors
Distinguished in New Daily Persistent Headache (NDPH)
Dr. Husam H. Alkhersam
Neurology
Distinguished in New Daily Persistent Headache (NDPH)
Dr. Husam H. Alkhersam
Neurology

Ms Neurological Center PLLC

1604 Hospital Pkwy, Suite 307, 
Bedford, TX 
 (20.5 miles away)
817-545-0900
Languages Spoken:
English
See accepted insurances

Husam Alkhersam is a Neurologist in Bedford, Texas. Dr. Alkhersam is rated as a Distinguished provider by MediFind in the treatment of New Daily Persistent Headache (NDPH). His top areas of expertise are New Daily Persistent Headache (NDPH), Memory Loss, Migraine, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Distinguished in New Daily Persistent Headache (NDPH)
Samantha S. Mccormick, PA
Physician Assistant | Neurology
Distinguished in New Daily Persistent Headache (NDPH)
Samantha S. Mccormick, PA
Physician Assistant | Neurology

University Of Texas Southwestern Medical Center At Dallas

5323 Harry Hines Blvd, 
Dallas, TX 
 (8.3 miles away)
214-645-8200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Samantha Mccormick is a Physician Assistant and a Neurologist in Dallas, Texas. Ms. Mccormick is rated as an Advanced provider by MediFind in the treatment of New Daily Persistent Headache (NDPH). Her top areas of expertise are New Daily Persistent Headache (NDPH), Migraine, Migraine with Brainstem Aura, and Cluster Headache.

Distinguished in New Daily Persistent Headache (NDPH)
Dr. Waleed H. El-Feky
Neurology
Distinguished in New Daily Persistent Headache (NDPH)
Dr. Waleed H. El-Feky
Neurology

Texas Neurology PA

6080 N Central Expy, Suite 100, 
Dallas, TX 
 (5.8 miles away)
214-827-3610
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Waleed El-Feky is a Neurologist in Dallas, Texas. Dr. El-Feky is rated as a Distinguished provider by MediFind in the treatment of New Daily Persistent Headache (NDPH). His top areas of expertise are Narcolepsy, Cerebellar Degeneration, Foot Drop, and Restless Legs Syndrome. Dr. El-Feky is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Friedman's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile